

Letter to the Editor

Monoclonal antibody Cam 5.2 targeted mainly CK8, but not CK18 — Comment on: “Chromophobe renal cell carcinoma with liposarcomatous dedifferentiation - report of a unique case. Int J Clin Exp Pathol. 2010 May 5; 3(5):534-40.”

Chang Kuang Leei^{*1}, Wea-Lung Lin^{*2}, Chih-Ping Han²⁻⁴

¹Department of Emergency Medicine, Chung-Shan Medical University Hospital, Taichung, Taiwan; ²Department of Pathology, School of Medicine, Chung-Shan Medical University and Chung-Shan Medical University Hospital, Taichung, Taiwan; ³Department of Obstetrics and Gynecology, Chung-Shan Medical University Hospital, Taichung, Taiwan; ⁴Clinical Trial Center, Chung-Shan Medical University Hospital, Taichung, Taiwan. *Equal contributors

Received August 8, 2010; accepted August 18, 2010; available online August 20, 2010

Dear Editor:

We read with great interest the contribution by Dr. Petersson et al regarding the report, entitled “Chromophobe renal cell carcinoma with liposarcomatous dedifferentiation - report of a unique case” [1]. The authors presented a good case report and implemented a comprehensive discussion; but the article contains an error in Table 1 that may misguide the readers. In the footnotes of Table 1, the authors have erroneously stated that Cam 5.2 targets CK,8,18 [1].

Becton Dickinson Biosciences (Franklin Lakes, NJ) manufactured and globally marketed the anti-cytokeratin CAM5.2, which is derived from the clone CAM5.2. This clone recognizes human cytokeratin intermediate filament proteins at 48 and 52 kDa, which are identified as cytokeratins 7 and 8, respectively. Occasionally, anti-cytokeratin CAM5.2 has been mistakenly believed to recognize cytokeratins 8 and 18, since previous results by Makin et al are attributed to breakdown products of cytokeratin 8, giving smaller molecular weight fractions on immunoblots [2]. However, Becton Dickinson Biosciences has revised the data sheet for CAM5.2 (B.D.) since 1997. It is now well known that CAM5.2 is specific for cytokeratin 8 and to a lesser extent for the closely related cytokeratin 7, but shows no reactivity with 18 [3, 4].

We believe this information is of great help to clarify the critical point that monoclonal antibody CAM5.2 recognized mainly CK8, but not CK18.

Please address correspondence to: Chih-Ping Han, MD, PhD, Department of Obstetrics and Gynecology, Chung-Shan Medical University Hospital, Taichung, Taiwan. Fax: 886-4-35073516, Tel: 886-4-24739595, E-mail: hanhaly@gmail.com

References

- [1] Petersson F, Michal M, Franco M et al. Chromophobe renal cell carcinoma with liposarcomatous dedifferentiation - report of a unique case. Int J Clin Exp Pathol. 2010 May 5;3(5):534-40.
- [2] Makin, C. A., L. G. Bobrow, et al. Monoclonal antibody to cytokeratin for use in routine histopathology. J Clin Pathol 1984; 37(9): 975-983.
- [3] BD Biosciences. Anti-cytokeratin (CAM 5.2) reagent for in vitro diagnostic use. 50 tests per vial - catalog no. 349205. Data sheet, Available at: http://www.bdbiosciences.com/external_files/is/doc/tds/Package_Inserts_IVD/live/web_enabled/23-3190-01_Cytokeratin_IVD.pdf. Accessed Aug 8, 2010.
- [4] BD Biosciences. Anti-Cytokeratin (CAM 5.2). Technical data sheet. Available at: http://www.bdbiosciences.com/external_files/is/doc/tds/Datasheets_RU0/live/web_enabled/23-1336-09-347653-347204-349205-DS-ruo.pdf. Accessed Aug 8, 2010.